Brokerages expect Becton Dickinson and Co (NYSE:BDX) to announce $3.06 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Becton Dickinson and’s earnings, with the lowest EPS estimate coming in at $2.96 and the highest estimate coming in at $3.20. Becton Dickinson and reported earnings of $2.91 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.2%. The business is expected to issue its next earnings results on Thursday, August 1st.
On average, analysts expect that Becton Dickinson and will report full year earnings of $11.69 per share for the current financial year, with EPS estimates ranging from $11.66 to $11.74. For the next year, analysts anticipate that the firm will post earnings of $13.05 per share, with EPS estimates ranging from $12.85 to $13.33. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Becton Dickinson and.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $0.02. The company had revenue of $4.20 billion for the quarter, compared to analyst estimates of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The firm’s revenue was down .6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.65 earnings per share.
BDX has been the topic of a number of research reports. Morgan Stanley lowered their target price on shares of Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating on the stock in a research report on Friday, May 10th. Barclays raised their target price on shares of Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Raymond James lowered their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating on the stock in a research report on Tuesday, March 19th. Zacks Investment Research lowered shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, April 22nd. Finally, KeyCorp restated an “overweight” rating and set a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and has an average rating of “Buy” and a consensus target price of $262.00.
In other Becton Dickinson and news, EVP Betty D. Larson sold 1,700 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the completion of the sale, the executive vice president now owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Patrick Kaltenbach sold 191 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $241.03, for a total value of $46,036.73. Following the completion of the sale, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,154 shares of company stock valued at $4,955,775. Corporate insiders own 0.12% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Harvest Group Wealth Management LLC purchased a new position in shares of Becton Dickinson and in the first quarter valued at $25,000. Pinnacle Financial Partners Inc. purchased a new position in shares of Becton Dickinson and in the first quarter valued at $29,000. RPG Investment Advisory LLC purchased a new position in shares of Becton Dickinson and in the first quarter valued at $32,000. Nalls Sherbakoff Group LLC purchased a new position in shares of Becton Dickinson and in the fourth quarter valued at $34,000. Finally, Aspire Private Capital LLC purchased a new position in shares of Becton Dickinson and in the fourth quarter valued at $39,000. 84.54% of the stock is owned by institutional investors.
Shares of BDX traded up $0.12 during mid-day trading on Wednesday, reaching $248.34. 48,917 shares of the company’s stock were exchanged, compared to its average volume of 1,279,829. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The stock has a market cap of $66.48 billion, a PE ratio of 22.56, a PEG ratio of 1.85 and a beta of 1.12. The stock’s fifty day simple moving average is $234.99. Becton Dickinson and has a 52-week low of $208.62 and a 52-week high of $265.87.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 1.24%. The ex-dividend date of this dividend is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.